Back to Results

ContraFect Corp (CFRXQ)

ContraFect Corp is a common stock listing on OTC Markets tied to a clinical-stage biotechnology company focused on therapeutic proteins and antibodies for serious infectious diseases. Its development pipeline has included Exebacase, a lysin in late-stage testing for Staphylococcus aureus, along with CF-370, an antibacterial candidate in early clinical development for Pseudomonas aeruginosa-related infections, and CF-296, an engineered lysin being studied for invasive staphylococcal infections, including joint and device-related cases. The company has also reported work on Exebacase for persistent MRSA bacteremia in COVID-19 patients and has a license agreement with Rockefeller University related to novel lysin candidates targeting gram-negative pathogens. ContraFect was incorporated in 2008 and is based in Yonkers, New York. In December 2023, it filed for voluntary liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Analyst Price Target	Analyst Target Upside/Downside	Dividend Yield	Market Cap
OTC-CFRX.Q	Not available	Not available	Not available	0.0%	0.01 K

Smart Snapshot

Stock Overview

A fast read of the company and market metrics currently supported by the latest data.

Company Profile

Sector

Healthcare

Index Membership

Strong Sell

Quality & Risk

Piotroski Score

0 K

Valuation • Fair Value

ContraFect Corp (OTC-CFRX.Q) Fair Value by Valuation Model

No usable valuation estimate is currently available for ContraFect Corp (OTC-CFRX.Q); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for ContraFect Corp (OTC-CFRX.Q). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for ContraFect Corp (OTC-CFRX.Q)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

Strong Sell

Current operating scale indicator.

Revenue Forecast

Strong Sell

Forward revenue estimate.

EBITDA

Biotechnology

Current operating profitability reference.

How to read profitability and growth

This section helps investors review ContraFect Corp (OTC-CFRX.Q) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for ContraFect Corp (OTC-CFRX.Q)

Review the financial quality and risk indicators currently supported by the latest data.

Piotroski Score

0 K

Weak quality score that deserves closer review.

Beneish M-Score

43.7 M

Higher caution zone on this screen.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for ContraFect Corp (OTC-CFRX.Q). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for ContraFect Corp (OTC-CFRX.Q)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for ContraFect Corp (OTC-CFRX.Q). No upcoming dividend amount or event date is currently available.

FAQ • Fast Investor Answers

ContraFect Corp (OTC-CFRX.Q) Stock FAQ

Data-supported answers about ContraFect Corp (OTC-CFRX.Q), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value

Not available

No reliable estimate from the currently supported inputs

A reliable fair value estimate is not currently available for ContraFect Corp (OTC-CFRX.Q). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The latest available data indicates no current dividend yield for ContraFect Corp (OTC-CFRX.Q).

The current market capitalization listed for ContraFect Corp is 0.01 K.

The ticker symbol for ContraFect Corp is OTC-CFRX.Q, and the stock is listed on OTC Markets.

ContraFect Corp (OTC-CFRX.Q) is listed on OTC Markets.